TRGFT-201 is a donor-derived, three-component allogeneic cell therapy (HSPCs / regulatory T cells / conventional T cells) for matched-donor myeloablative stem cell transplantation in adults with hematological malignancies to improve chronic GVHD-free survival. It is a precision-engineered graft composed of three cell populations isolated from an HLA-matched donor's mobilized peripheral blood — purified hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons)...
- Also known as
- TregGraft
- Code names
- TRGFT-201
What you can answer from here — as of September 03, 2026
Which other approved drugs treat the same conditions as TRGFT-201, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account